Skip to Content

Korlym Approval History

  • FDA approved: Yes (First approved February 17th, 2012)
  • Brand name: Korlym
  • Generic name: mifepristone
  • Dosage form: Tablets
  • Company: Corcept Therapeutics
  • Treatment for: Cushing's Syndrome

Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance.

Development History and FDA Approval Process for Korlym

Feb 17, 2012Approval FDA Approves Korlym for Patients with Endogenous Cushing's Syndrome

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.